India trials for Russia's 'Sputnik-V' vaccine could start in next few weeks: Executive

Indian trials of the Sputnik-V vaccine candidate, being developed by Russia's sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country, Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy's, told Reuters.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news